welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Avidity Biosciences Receives Investment from CureDuchenne
Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, announced today that CureDuchenne has made an equity investment in the company. Funding will help to advance pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).
rareRelated
-
Summit announces PhaseOut DMD did not meet primary endpointSummit Therapeutics announced today that...
-
Bespoke Is Often Better: How Scientists Are Customizing Gene TherapyWhen it comes to products from suits to ...
-
HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)Male subjects with cardiomyopathy second...
-
Exon Skipping Explained from Sarepta Therapeuticshttps://player.vimeo.com/video/238953537...
-
CureDuchenneCureDuchenne is recognized as the global...
-
BIOPHYTIS to Host Key Opinion Leader Meeting on the Biology of Aging and its Application in Neuromuscular DiseasesBiophytis, a clinical-stage biotechnolog...